Det er derfor usandsynligt, at Fablyn ændrer farmakokinetikken af lægemidler, der metaboliseres via disse CYP- isoformer eller transporteres af MDR1 P- glycoprotein.
Therefore FABLYN is unlikely to alter the pharmacokinetics of medicinal products that are cleared by metabolism via these CYP isoforms, or are transported by MDR1 P-glycoprotein.